^
6d
24-Week Recurrence Rate of Gout Following Firsekibart Treatment (clinicaltrials.gov)
P=N/A, N=264, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
New trial • Real-world evidence
|
Jin Beixin (firsekibart)
9d
New trial
|
Jin Beixin (firsekibart)
2ms
A multicenter, prospective, basket interventional study of vixencizumab in the treatment of CAPS, FMF, Schnitzler syndrome and AOSD (ChiCTR2600120336)
P=N/A, N=90, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
New trial
|
NLRP3 (NLR Family Pyrin Domain Containing 3)
|
Jin Beixin (firsekibart)
2ms
New P4 trial
|
Jin Beixin (firsekibart)
2ms
Clinical Effectiveness and Safety of IL-1 Inhibitors Plus Urate-Lowering Therapy Compared to Conventional Treatment in Patients with Refractory Gout: A Real-World Study (ChiCTR2600119208)
P=N/A, N=56, Tianjin Medical University Chu Hsien-I Memorial Hospital; Tianjin Medical University Chu Hsien-I Memorial?Hospital
New trial • Real-world evidence
|
Jin Beixin (firsekibart)
2ms
New trial
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Jin Beixin (firsekibart)
2ms
A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease (clinicaltrials.gov)
P=N/A, N=20, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
Enrollment open
|
Jin Beixin (firsekibart) • Kineret (anakinra)
2ms
New trial
|
Jin Beixin (firsekibart)
7ms
Efficacy and Safety of Firsekibart versus Anakinra in Adult-Onset Still's Disease (ChiCTR2500109835)
P4, N=20, Not yet recruiting, Ruijin Hospital, Shanghai JiaoTong University School of Medicine; Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai
New P4 trial
|
Jin Beixin (firsekibart) • Kineret (anakinra)
9ms
New trial
|
Jin Beixin (firsekibart) • Kineret (anakinra)
1year
Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults (clinicaltrials.gov)
P1, N=24, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Completed
Trial completion
|
Jin Beixin (firsekibart)
over1year
Clinical Study of Genakumab for Injection in Patients With Acute Gout (clinicaltrials.gov)
P1/2, N=121, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed
Trial completion
|
Jin Beixin (firsekibart)